CTXRNasdaqPharmaceutical PreparationsFiscal year ends September 30
Citius Pharmaceuticals, Inc.
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.43−0.03 (-7.00%)
Close on Oct 19, 2026
- Market cap
- $11.20M
- P/E (TTM)
- –
- Dividend yield
- –
Citius Pharmaceuticals, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q3 26 | Q2 26 | Q1 26 | % of revenue |
|---|---|---|---|---|
| Gross Product Revenue [Member] | $1.71M | $2.00M | $4.88M | 114.4% |
| Gross-to-net Adjustments [Member] | $214.77K | $336.46K | $934.61K | 14.4% |
By region
From the segment and revenue-disaggregation notes of Citius Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.